FDA Advisory Panel Backs Six Peptides for 503A Bulks-List ConsiderationThe FDA Pharmacy Compounding Advisory Committee recommended six peptide bulk substances for 503A list consideration after two days of safety, sourcing, and dosing testimony in July 2026.
